Navigation Links
Aspirin reduces cardiovascular risks in men and women -- but differently

Aspirin can significantly reduce the risk of cardiovascular events -- a combined endpoint including stroke, heart attack and death due to cardiovascular disease -- in both men and women, according to a new meta-analysis of more than 95,000 patients by a Duke University Medical Center cardiologist.

However, the researchers found, the major reasons for the risk reduction differed between the sexes. For men, aspirin lowered the risk of a heart attack, while in women, aspirin reduced the risk of a stroke.

The use of aspirin, however, also carries an increased risk of bleeding among both sexes, the study found. The results of the new analysis lead the researchers to recommend that all patients and physicians should discuss the benefits and drawbacks of regularly taking aspirin as a preventative measure against cardiovascular events.

"Aspirin is a drug that has been used for many years ?it is well-understood, effective, inexpensive and widely available," said Duke cardiology fellow Jeffrey Berger, M.D, first author of a paper published Jan. 18, 2006, in the Journal of the American Medical Association. He performed much of the research while at Beth Israel Medical Center, New York, under senior author cardiologist David Brown, M.D.

"This is good news because many of the past studies of the effect of aspirin in preventing cardiovascular events looked only at men, so physicians were reluctant to prescribe aspirin for women because there was little data," Berger continued. "But now, the combined data of recent trials involving women demonstrates that women can benefit just as much from aspirin therapy as men."

Berger emphasized that more healthy men and women who can tolerate aspirin should be taking the medication for the prevention of cardiovascular disease. It is estimated that fewer than five percent of the population suffers from the known gastrointestinal side effects of aspirin or are allergic to it, meaning that many more serious cardiovascular events could be prevented if aspirin was more widely used, Berger said

In his analysis, Berger combined the data from six different randomized clinical trials, which yielded a total of 95,456 patients, none of whom had coronary artery disease. Of that total, 51,342 were women. The trials all involved the comparison of low-dose aspirin versus placebo for the primary prevention of cardiovascular disease.

The analysis revealed that aspirin conferred a 12 percent reduction in risk in cardiovascular events for women, and a 14 percent reduction for men.

"Our findings are particularly noteworthy in that aspirin's main beneficial effects appeared to be the reduction in the risk of stroke for women and reduction in the risk of heart attacks for men," Berger said. "While our analysis showed that aspirin may have different effects in men and women, the relatively small number of heart attacks among women and strokes among men suggest that more research is needed to better understand any differences in cardiovascular responses to aspirin."

Specifically, among the 51,342 women in the analysis, there were 625 strokes and 469 heart attacks. Among the 44,114 men, there were 597 strokes and 1,023 heart attacks.

However, the routine use of aspirin does not come without potential risks, especially in terms of major bleeding episodes. The analysis found that routine aspirin use for an average of 6.4 years would lead to 2.5 major bleeding events per 1,000 women and 3 major bleeding events per 1,000 men.

"For this reason, while we believe that many more people could benefit from taking aspirin, it is important for patients and their physicians to discuss the issue and weigh the benefits and potential drawbacks to this therapy," Berger said. "Also, aspirin should never replace other ways of reducing cardiovascular risks, such eating a proper diet and exercising."

Of the six randomized clinical trials involved in the a nalysis, three enrolled solely men, one included only women, and two enrolled both sexes. The trials were: Physicians Health Study, British Doctor's Trial, Thrombosis Prevention Trial, Hypertension Optimal Treatment Trial, Primary Prevention Project and the Women's Health Study.


'"/>

Source:Duke University Medical Center


Related biology news :

1. Aspirin discovery may improve cancer treatments
2. Male circumcision reduces risk of HIV transmission from women to men
3. Deficiency of growth hormone and IGF-1 reduces cancer and kidney disease, but creates other problems
4. New miniaturised chip dramatically reduces time taken for DNA analysis
5. New processing method reduces peanut allergenicity
6. Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke
7. Study finds that nutritionally enhanced rice reduces iron deficiency
8. Overfishing in inland waters reduces biodiversity and threatens health
9. New gene reduces retinal degeneration in fruit flies
10. Prenatal nicotine exposure reduces breathing response of newborns...
11. Heat-shock protein vaccine reduces alveolar bone loss
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/25/2016)... 25, 2016  Glencoe Software, the world-leading supplier of ... industries, will provide the data management solution OMERO Plus ... Photo - ... Phenotypic analysis measures the characteristics and ... comparisons between states such as health and disease, the ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):
(Date:2/11/2016)...   BioInformant announces the February 2016 release ... Opportunities, Tools, and Technologies – Market Size, Segments, Trends, ... The first and only market ... BioInformant has more than a decade of historical information ... stem cell type. This powerful 175 page global strategic ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cell treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols ... patients from around the world. , The new GSCG clinic is headed ...
(Date:2/10/2016)... Feb. 10, 2016  The Maryland House of Delegates ... announced that University of Maryland School of Medicine Dean ... University of Maryland Medical System President and CEO ... Medallion," the highest honor given to the public by ... Dean Reece and Mr. Chrencik for their ...
(Date:2/10/2016)... New York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it ... and develop new vaccines and immunotherapies for infectious diseases and cancer. ...
Breaking Biology Technology: